The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval:-0.30 to 0.80) (P=0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R 2 to 0.50 with a slope of 1.44 (P=0.0021). Abiraterone is a well-Tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.

Cicero, G., DE LUCA, R., Blasi, L., Pepe, A., Pavone, C., Simonato, A., et al. (2017). Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study. ANTI-CANCER DRUGS, 28(9), 1047-1052 [10.1097/CAD.0000000000000549].

Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study

CICERO, Giuseppe;DE LUCA, Rossella;PAVONE, Carlo;Simonato, Alchiede;DIELI, Francesco
2017-01-01

Abstract

The aim of this study was to evaluate abiraterone's efficacy in Italian patients affected with metastatic prostate cancer progressing after treatment with docetaxel. We conducted a retrospective analysis of 60 patients. Prostate-specific antigen (PSA) reduction in serum was the primary endpoint for evaluating the efficacy of abiraterone in combination with prednisone treatment, whereas reduced pain, safety, progression-free survival, response rate, and overall survival (OS) were secondary endpoints. A significant correlation was noticed between PSA response and OS. Further, the Index Bravais-Pearson (r) correlation allowed us to observe a significant negative interdependence between PSA response and reduction in pain of 0.57 (95% confidence interval:-0.30 to 0.80) (P=0.005). Meanwhile, regression analysis revealed that PSA levels are predictive of OS. There was a positive correlation with OS, which showed a value of R 2 to 0.50 with a slope of 1.44 (P=0.0021). Abiraterone is a well-Tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer. The drug has a better tolerability profile, gives significant pain relief, and increases the survival rate.
http://journals.lww.com/anti-cancerdrugs/pages/default.aspx
Cicero, G., DE LUCA, R., Blasi, L., Pepe, A., Pavone, C., Simonato, A., et al. (2017). Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: A retrospective study. ANTI-CANCER DRUGS, 28(9), 1047-1052 [10.1097/CAD.0000000000000549].
File in questo prodotto:
File Dimensione Formato  
2017 abiraterone.pdf

Solo gestori archvio

Dimensione 130.17 kB
Formato Adobe PDF
130.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/244652
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact